Literature DB >> 30507075

Novel nano-microspheres containing chitosan, hyaluronic acid, and chondroitin sulfate deliver growth and differentiation factor-5 plasmid for osteoarthritis gene therapy.

Zhu Chen1, Shang Deng1,2, De-Chao Yuan1,3, Kang Liu1, Xiao-Cong Xiang1, Liang Cheng4, Dong-Qin Xiao1, Li Deng1, Gang Feng1.   

Abstract

OBJECTIVE: To construct a novel non-viral vector loaded with growth and differentiation factor-5 (GDF-5) plasmid using chitosan, hyaluronic acid, and chondroitin sulfate for osteoarthritis (OA) gene therapy.
METHODS: Nano-microspheres (NMPs) were prepared by mixing chitosan, hyaluronic acid, and chondroitin sulfate. GDF-5 plasmid was encapsulated in the NMPs through electrostatic adsorption. The basic characteristics of the NMPs were observed, and then they were co-cultured with chondrocytes to observe their effects on extracellular matrix (ECM) protein expression. Finally, NMPs loaded with GDF-5 were injected into the articular cavities of rabbits to observe their therapeutic effects on OA in vivo.
RESULTS: NMPs exhibited good physicochemical properties and low cytotoxicity. Their average diameter was (0.61±0.20) μm, and encapsulation efficiency was (38.19±0.36)%. According to Cell Counting Kit-8 (CCK-8) assay, relative cell viability was 75%-99% when the total weight of NMPs was less than 560 μg. Transfection efficiency was (62.0±2.1)% in a liposome group, and (60.0±1.8)% in the NMP group. There was no significant difference between the two groups (P>0.05). Immunohistochemical staining results suggested that NMPs can successfully transfect chondrocytes and stimulate ECM protein expression in vitro. Compared with the control groups, the NMP group significantly promoted the expression of chondrocyte ECM in vivo (P<0.05), as shown by analysis of the biochemical composition of chondrocyte ECM. When NMPs were injected into OA model rabbits, the expression of ECM proteins in chondrocytes was significantly promoted and the progression of OA was slowed down.
CONCLUSIONS: Based on these data, we think that these NMPs with excellent physicochemical and biological properties could be promising non-viral vectors for OA gene therapy.

Entities:  

Keywords:  Osteoarthritis; Gene therapy; Chitosan; Hyaluronic acid; Chondroitin sulfate; Growth and differentiation factor-5 (GDF-5) plasmid

Mesh:

Substances:

Year:  2018        PMID: 30507075      PMCID: PMC6305252          DOI: 10.1631/jzus.B1800095

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  35 in total

1.  Radiological assessment of osteo-arthrosis.

Authors:  J H KELLGREN; J S LAWRENCE
Journal:  Ann Rheum Dis       Date:  1957-12       Impact factor: 19.103

2.  Lateral compartment osteoarthritis of the knee after meniscectomy treated by the transplantation of tissue-engineered cartilage and osteochondral plug.

Authors:  Nobuo Adachi; Mitsuo Ochi; Masataka Deie; Yohei Ito; Yasunori Izuta
Journal:  Arthroscopy       Date:  2006-01       Impact factor: 4.772

Review 3.  Osteoarthritis year 2011 in review: clinical.

Authors:  T E McAlindon; J B Driban; G H Lo
Journal:  Osteoarthritis Cartilage       Date:  2012-01-14       Impact factor: 6.576

Review 4.  Viscosupplementation with intra-articular hyaluronic acid for treatment of osteoarthritis in the elderly.

Authors:  M Abate; D Pulcini; A Di Iorio; C Schiavone
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

5.  Novel hyaluronic acid-chitosan nanoparticles as non-viral gene delivery vectors targeting osteoarthritis.

Authors:  Hua-Ding Lu; Hui-Qing Zhao; Kun Wang; Lu-Lu Lv
Journal:  Int J Pharm       Date:  2011-09-03       Impact factor: 5.875

Review 6.  New molecular targets for the treatment of osteoarthritis.

Authors:  Maria José Alcaraz; Javier Megías; Isabel García-Arnandis; Victoria Clérigues; Maria Isabel Guillén
Journal:  Biochem Pharmacol       Date:  2010-03-03       Impact factor: 5.858

7.  Increased life span of human osteoarthritic chondrocytes by exogenous expression of telomerase.

Authors:  Sonsoles Piera-Velazquez; Sergio A Jimenez; DavidG Stokes
Journal:  Arthritis Rheum       Date:  2002-03

8.  Delayed fracture healing in growth differentiation factor 5-deficient mice: a pilot study.

Authors:  Cynthia M Coleman; Brooke H Scheremeta; Amanda T Boyce; Robert L Mauck; Rocky S Tuan
Journal:  Clin Orthop Relat Res       Date:  2011-05-18       Impact factor: 4.176

9.  Adenovirus-mediated expression of growth and differentiation factor-5 promotes chondrogenesis of adipose stem cells.

Authors:  Gang Feng; Yuqing Wan; Gary Balian; Cato T Laurencin; Xudong Li
Journal:  Growth Factors       Date:  2008-06       Impact factor: 2.511

10.  International Cartilage Repair Society (ICRS) and Oswestry macroscopic cartilage evaluation scores validated for use in Autologous Chondrocyte Implantation (ACI) and microfracture.

Authors:  M P J van den Borne; N J H Raijmakers; J Vanlauwe; J Victor; S N de Jong; J Bellemans; D B F Saris
Journal:  Osteoarthritis Cartilage       Date:  2007-07-02       Impact factor: 6.576

View more
  3 in total

1.  Hyaluronic acid derivative-modified nano-structured lipid carrier for cancer targeting and therapy.

Authors:  Xiao Liu; Hai Liu; Su-Lan Wang; Jing-Wen Liu
Journal:  J Zhejiang Univ Sci B       Date:  2020-07       Impact factor: 3.066

2.  Catalpol ameliorates LPS-induced endometritis by inhibiting inflammation and TLR4/NF-κB signaling.

Authors:  Hua Zhang; Zhi-Min Wu; Ya-Ping Yang; Aftab Shaukat; Jing Yang; Ying-Fang Guo; Tao Zhang; Xin-Ying Zhu; Jin-Xia Qiu; Gan-Zhen Deng; Dong-Mei Shi
Journal:  J Zhejiang Univ Sci B       Date:  2019 Oct.       Impact factor: 3.066

Review 3.  Current Insights Into the Maintenance of Structure and Function of Intervertebral Disc: A Review of the Regulatory Role of Growth and Differentiation Factor-5.

Authors:  Bin Lv; Weikang Gan; Zhangrong Cheng; Juntao Wu; Yuhang Chen; Kangchen Zhao; Yukun Zhang
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.